Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Emery, P; Vencovský, J; Ghil, J; Won Kang, J (2016)
Publisher: BMJ Publishing Group
Languages: English
Types: Article
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2015.
    • 2. Moots RJ, Balsa A, Wolbink G. Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required. Ann Rheum Dis 2016.
    • 3. Emery P, Vencovsky J, Ghil J. Response to: 'Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required' by Moots et al. Ann Rheum Dis 2016.
    • 4. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25(1):40-6.
    • 5. Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29(2):238-47.
    • 6. Hoshino M, Yoshio T, Onishi S, et al. Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2012;22(4):532-40.
    • 7. Daien CI, Daien V, Parussini E, et al. Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study. J Rheumatol 2012;39(8):1533-8.
    • 8. Jamnitski A, Krieckaert CL, Nurmohamed MT, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71(1):88-91.
    • 9. Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet 2015;385 Suppl 1:S48.
    • 10. Krieckaert CL, Jamnitski A, Nurmohamed MT, et al. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012;64(12):3850-5.
    • 11. Udata C, Yin D, Cai C, et al. Immunogenicity Assessment of PF-06438179, A Potential Biosimilar to Infliximab, In Healthy Volunteers. Ann Rheum Dis 2015;74:Suppl 2 702 doi:10.1136/annrheumdis-2015-eular.4209.
    • 12. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72(10):1605-12.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article